Apyrase to treat ischemia/reperfusion injury during lung transplantation

Information

  • Research Project
  • 7778848
  • ApplicationId
    7778848
  • Core Project Number
    R44HL087456
  • Full Project Number
    5R44HL087456-03
  • Serial Number
    87456
  • FOA Number
    PA-08-050
  • Sub Project Id
  • Project Start Date
    5/1/2007 - 18 years ago
  • Project End Date
    6/30/2012 - 13 years ago
  • Program Officer Name
    REYNOLDS, HERBERT Y
  • Budget Start Date
    3/1/2010 - 15 years ago
  • Budget End Date
    6/30/2012 - 13 years ago
  • Fiscal Year
    2010
  • Support Year
    3
  • Suffix
  • Award Notice Date
    2/25/2010 - 15 years ago
Organizations

Apyrase to treat ischemia/reperfusion injury during lung transplantation

DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy to prevent or reduce ischemia-reperfusion injury during lung transplantation. The enzyme strongly preserves vascular integrity and inhibits platelet activation and aggregation without increasing bleeding risk. Using a protein informatics approach, we have successfully engineered an optimized human apyrase, APT102. With Phase II grant support, We will determine whether APT102 improves lung allograft function without increasing bleeding risk in clinically relevant models of allogeneic orthotopic lung transplantation in rats and dogs. The ultimate goal is to demonstrate whether APT102 has the potential to be a therapy for transplantation-associated and other vascular diseases. PUBLIC HEALTH RELEVANCE: We will determine whether human apyrase improves lung allograft function without increasing bleeding risk in clinically relevant models of allogeneic orthotopic lung transplantation in rats and dogs.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R44
  • Administering IC
    HL
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    439052
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
    NHLBI:439052\
  • Funding Mechanism
    SBIR-STTR
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    APT THERAPEUTICS, INC.
  • Organization Department
  • Organization DUNS
    192266141
  • Organization City
    SAINT LOUIS
  • Organization State
    MO
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    631083213
  • Organization District
    UNITED STATES